Inspire Pharmaceuticals — CEUT Emerging Growth Conference 2007
26 slides from Inspire Pharmaceuticals's conference presentation, Jul 11, 2007
Slide 1: CEUT Emerging Growth Conference
CEUT EMERGING GROWTH CONFERENCE July 11, 2007 CEUT EMERGING CEUT EMERGING GROWTH CONFERENCE GROWTH CONFERENCE July 11, 2007 July 11, 2007 Exhibit 99.1
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements Forward-Looking Statements This presentation contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995 which convey management's expectations, beliefs, plans and objectives regarding future performance. These statements discus
Slide 3: Inspire: An Integrated Company With a Therapeutic Focus
3 Inspire: An Integrated Company With a Therapeutic Focus Inspire: An Integrated Company With a Therapeutic Focus Vertically-integrated with R&D and commercial capabilities Therapeutic focus in ophthalmology & respiratory/ allergy Specialized sales force generating attractive revenue stream Robust p
Slide 4: Inspire's Balanced and Growing Portfolio
4 Inspire’s Balanced and Growing Portfolio Elestat ® for allergic conjunctivitis Restasis ® for dry eye Glaucoma Prolacria ™ for dry eye AzaSite ™ for bacterial conjunctivitis Inspire’s Balanced and Growing Portfolio Approved NDA Filed Phase 3 Phase 2 Phase 1 Bilastine Oral for allergic rhinitis (AR
Slide 5: Attractive Stream of Revenues
5 Attractive Stream of Revenues Attractive Stream of Revenues $23 mm $45 - 57 mm* Inspire Annual Revenues $11 mm Elestat ® Restasis ® *Guidance provided on 5/9/07 $37 mm $76 million cash & investments balance, as of 3/31/07 $40 million debt 2007 Guidance* Aggregate revenue of $45 to $57 million Oper
Slide 6: Ophthalmic Products and Pipeline Programs
6 Ophthalmic Products and Pipeline Programs Ophthalmic Products and Pipeline Programs
Slide 7: Commercial Infrastructure Leveraged With Three Products
7 Commercial Infrastructure Leveraged With Three Products Commercial Infrastructure Leveraged With Three Products
Slide 8: Differentiated Product for Bacterial Conjunctivitis
8 Differentiated Product for Bacterial Conjunctivitis Differentiated Product for Bacterial Conjunctivitis Approved by FDA on April 27, 2007 Launch expected in mid-August 2007 Licensed Feb. 2007 from InSite Vision Well-known broad spectrum antibiotic Convenient dosing regimen Approved for patients on
Slide 9: Reduced Dosing Regimen Compared to Other Products
9 Day 5 Day 4 Day 7 Day 6 Day 3 Day 2 Day 1 Day 5 Day 4 Day 7 Day 6 Day 3 Day 2 Day 1 Reduced Dosing Regimen Compared to Other Products Reduced Dosing Regimen Compared to Other Products AzaSite ™ – 9 drops per affected eye Current market leader – 21 drops per affected eye
Slide 10: Attractive Bacterial Conjunctivitis Market
10 Attractive Bacterial Conjunctivitis Market Attractive Bacterial Conjunctivitis Market *Market share based on single-entity products for the 12 months ended 12/31/06; Source: IMS **Guidance provided on April 27, 2007 $362 million annual U.S. prescription sales* AzaSite ™ 2008 Target Sales of $30 –
Slide 11: Current Market Provides Targeting Opportunities
11 Current Market Provides Targeting Opportunities Current Market Provides Targeting Opportunities *Data based on single-entity products for the 12 months ended 12/31/06; Source: IMS 15 million U.S. ophthalmic anti-infective prescriptions in 2006* Inspire’s sales force will target top prescribers wr
Slide 12: Elestat - Competitive Allergic Conjunctivitis Product
12 Elestat ® - Competitive Allergic Conjunctivitis Product Elestat ® - Competitive Allergic Conjunctivitis Product Prevents ocular allergy symptoms by Blocking H and H receptors Stabilizing mast cells Stopping progression of pro-inflammatory mediators Important features Low affinity for M Soothing u
Slide 13: Large and Growing Allergic Conjunctivitis Market
13 Large and Growing Allergic Conjunctivitis Market Large and Growing Allergic Conjunctivitis Market $476 million annual U.S. prescription sales* 45% of total prescriptions are written by eye care and allergy specialists* *12 months ended 12/31/06; Source: IMS Patanol® Elestat® Optivar® Zaditor® & G
Slide 14: Dry Eye Affects 30 Million Patients in Major Markets
14 Dry Eye Affects 30 Million Patients in Major Markets Signs/Symptoms Treatments Causes Dry Eye Affects 30 Million Patients in Major Markets Corneal damage Foreign body sensation Persistent irritation/redness Light sensitivity Pain/burning Impaired vision Signs/Symptoms Limited treatment options Re
Slide 15: Strong and Continued Growth of Restasis
15 Strong and Continued Growth of Restasis ® Strong and Continued Growth of Restasis ® * Allergan estimate (5/2/07) $100 mm $270 mm $320 - 340 mm Total Global Sales of Restasis as Reported by Allergan $38 mm $191 mm 2003 2004 2005 2006 2007 est*
Slide 16: Prolacria - A Unique Mechanism of Action for Dry Eye
16 Prolacria ™ – A Unique Mechanism of Action for Dry Eye Prolacria ™ – A Unique Mechanism of Action for Dry Eye Internally-developed P2Y agonist Promotes release of components of natural tear-film (fluid, mucin and lipids) Good tolerability and safety profile Excellent proprietary position Two appr
Slide 17: Novel Glaucoma Program
17 Novel Glaucoma Program Novel Glaucoma Program Leading cause of preventable blindness in U.S. Largest market in ophthalmic pharmaceuticals - $1.7 billion in annual prescription sales* Unique technology platform licensed from Wisconsin Alumni Research Foundation Novel approach to lowering IOP by ta
Slide 18: Respiratory/Allergy Pipeline Programs
18 Respiratory/Allergy Pipeline Programs Respiratory/Allergy Pipeline Programs
Slide 19: Cystic Fibrosis: Life Threatening, Genetic Disease
19 Cystic Fibrosis: Life Threatening, Genetic Disease Cystic Fibrosis: Life Threatening, Genetic Disease Snapshot of CF’s Impact: ~ 30,000 U.S. patients; 75,000 worldwide Life expectancy: ~ 37 yrs 90% of CF patients die of respiratory failure Two-third’s of CF patients have mild disease 60% of CF po
Slide 20: Phase 3 Program: Denufosol is an Early Intervention Approach
20 Phase 3 Program: Denufosol is an Early Intervention Approach Phase 3 Program: Denufosol is an Early Intervention Approach Phase 3 program focused on early intervention for patients with mild lung disease Two Phase 3 clinical efficacy trials planned First trial, TIGER - 1 , ongoing in U.S. - Enrol
Slide 21: High Prevalence of Allergic Rhinitis
21 High Prevalence of Allergic Rhinitis High Prevalence of Allergic Rhinitis 40 million people in U.S. suffer from allergic rhinitis th leading cause of chronic disease in U.S. 17 million office visits per year Annual cost of allergy disease estimated at $7 billion *Sources: American Academy of Alle
Slide 22: Bilastine - Antihistamine Licensed from FAES FARMA
22 Bilastine – Antihistamine Licensed from FAES FARMA Bilastine – Antihistamine Licensed from FAES FARMA Licensed U.S./ Canadian rights for bilastine from FAES in 2006 Once-daily, oral, highly selective H -antihistamine Composition of matter patent through 2017 Two large positive Phase 3 comparative
Slide 23: Epinastine Nasal Spray: Advancing to Phase 3
23 Epinastine Nasal Spray: Advancing to Phase 3 Licensed U.S./ Canadian rights for epinastine nasal spray for rhinitis from Boehringer Ingelheim in 2006 Positive results in Phase 2 trial 14-day trial in 569 subjects in mountain cedar pollen season Met primary endpoint of reflective total nasal sympt
Slide 24: Attractive Market for Nasal Treatment of Allergic Rhinitis
24 Attractive Market for Nasal Treatment of Allergic Rhinitis Attractive Market for Nasal Treatment of Allergic Rhinitis $2.7 billion annual U.S. prescription sales* * Information is for 12 months ended 12/31/06; Source: IMS ** Source: American Academy of Allergy, Asthma & Immunology million patient
Slide 25: Key Milestone and Catalysts in 2007
25 Key Milestone and Catalysts in 2007 In-licensed and received FDA approval of AzaSite Reported positive results in Phase 2 epinastine nasal spray mountain cedar trial Met with FDA regarding next steps for oral bilastine - Amended FAES agreement Met with FDA regarding next steps for epinastine nasa
Slide 26: CEUT Emerging Growth Conference
CEUT EMERGING GROWTH CONFERENCE July 11, 2007 CEUT EMERGING CEUT EMERGING GROWTH CONFERENCE GROWTH CONFERENCE July 11, 2007 July 11, 2007
Inspire Pharmaceuticals — CEUT Emerging Growth Conference 2007 on 6ix